NEWS & MEDIA

 

Stemtek Therapeutcis is one of the top 8 innovations of May!

This spotlight gives us the opportunity to get the word out about us and our work towards accelerating early drug discovery. - May 22, 2017

Scientist is a web-based marketplace that connects the scientific community by providing easy access to information of different suppliers, researchers and enterprises. They are on the cutting edge of innovation happening in the industry and this month CELL2SPHERE™ has been selected as one of the top 8 innovation picks that represents the most ground breaking technologies on the planet. 

This spotlight gives us the opportunity to get the word out about us and our work towards accelerating early drug discovery with enhanced biological relevance assays 3D-based cell cultures.  With this goal we created Cell2Sphere™, a ready to use 3D cell culture kit will help advance drug development projects by providing a fast, biologically relevant and easy to use tool to screen the activity of test compounds in 3D cell culture. It is delivered frozen for flexible and convenient experiment planning.  We at StemTek are so convinced that Cell2Sphere will help advance significantly cancer therapeutics research.  These spheroids are grown from cancer stem cell enriched cultures, as a surrogate model for tumor formation.  Cell2Sphere™ technology allows study cell-cell interactions, cell signaling mechanisms, and allows for the preservation of metabolic gradients. The result is more comprehensive, accurate, and reproducible data helping scientists achieve drug discovery success.

Founded in 2013, StemTek is a biotech startup entirely dedicated to cancer cell research and drug discovery. StemTek uses 3D cell based assay automated for HTS, allowing the company to test thousands of compounds that target cancer stem cells to stop spheroid formation. 3D cell culture systems allow for stronger, more efficient and reliable drug screening. StemTek collaborates with pharmaceutical and biotech companies to accelerate early stage drug screening to develop new anticancer therapies. With over thirty years combined experience in molecular and cellular oncology, StemTek’s goal is to find treatments that put an end to relapse.

 
Back to top